Latanoprost Versus Fotil

Pharmaceutical Research Network

Status and phase: Completed; Phase 4

Conditions: Open-Angle Glaucoma; Ocular Hypertension

Treatments: Drug: Fotil; Drug: placebo; Drug: latanoprost 0.005%

Study type: Interventional

Funder types: Other

Identifiers

NCT00304785

PRN 03-026

Details and patient eligibility

About

To compare the intraocular pressure effect and safety of latanoprost 0.005% given every evening versus PTFC given twice daily.

Enrollment: 36 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• adults with primary open-angle or pigment dispersion glaucoma, or ocular hypertension
• untreated intraocular pressure should be between 24-36 mm Hg inclusive
• visual acuity should be 5/50 or better in both eyes

Exclusion criteria

• presence of exfoliation syndrome or exfoliation glaucoma
• contraindications to study medications
• any anticipated change in systemic hypotensive therapy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind